CRYSTAL LAKE, Ill.--(BUSINESS WIRE)-- AptarGroup, Inc. (ATR), a global leader in drug delivery and consumer product dosing, dispensing and protection technologies, today shared an overview of its ...
(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current spot rates for all applicable foreign currency ...
(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using spot rates as of December 31, 2024 for all applicable foreign ...
TYRVAYA™, a highly selective cholinergic agonist, is the first nasally-administered pharmaceutical therapy to treat the signs and symptoms of dry eye disease to have been approved by the U.S. FDA.
Beat the Blink is a new eye care delivery system designed to improve dosing precision and enhance patient experience by “beating the blink” reflex. Aptar’s technology aims to address an unmet need: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results